[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR850007261A - 옥타하이드로티아졸로[4,5-ｇ]퀴놀린의 제조방법 - Google Patents

옥타하이드로티아졸로[4,5-ｇ]퀴놀린의 제조방법 Download PDF

Info

Publication number
KR850007261A
KR850007261A KR1019850002803A KR850002803A KR850007261A KR 850007261 A KR850007261 A KR 850007261A KR 1019850002803 A KR1019850002803 A KR 1019850002803A KR 850002803 A KR850002803 A KR 850002803A KR 850007261 A KR850007261 A KR 850007261A
Authority
KR
South Korea
Prior art keywords
propyl
trans
formula
compound
methyl
Prior art date
Application number
KR1019850002803A
Other languages
English (en)
Other versions
KR870001072B1 (ko
Inventor
다니엘 티투스 로버트 (외 1)
Original Assignee
메리 앤 터커
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메리 앤 터커, 일라이 릴리 앤드 캄파니 filed Critical 메리 앤 터커
Publication of KR850007261A publication Critical patent/KR850007261A/ko
Application granted granted Critical
Publication of KR870001072B1 publication Critical patent/KR870001072B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/30—Metal salts; Chelates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음

Description

옥타하이드로티아졸로[4,5-g] 퀴놀린의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. (a) 일반식(Ⅴ) 화합물을 일반식(Ⅳ) 화합물로 폐환시켜 R이 H, 벤질, 메틸, 에틸 또는 n-프로필이고, R1이 H, 메틸, NH2, NH(C1내지 C3알킬), N-(C1내지 C3알킬)2또는 NH(C1내지 C2알킬페닐인 일반식 (Ⅰ)화합물을 생성시키거나;
    (b) 일반식(Ⅰa) 화합물을 일반식(A) 화합물로 아실화시켜 R이 메틸, 에틸, n-프로필, 알릴(또는 벤질이고, R1이 -NH-CO-C1내지 C3알킬인 일반식(Ⅰ) 화합물을 생성시키거나;
    (c) 일반식(Ⅰb) 화합물을 수성차아인산과 반응시켜 R이 메틸, 에틸, n-프로필, 알릴이고, R1이 H인 일반식(Ⅰ) 화합물을 생성시키거나, 구리이온공급원 및 HBr또는 HCl과 반응시켜 R이 메틸, 에틸, n-프로필, 알릴 도는 벤질이고 R1이 Cl 또는 Br인 일반식(Ⅰ)화합물을 생성시키거나;
    (d) 일반식(Ⅰc) 화합물을 산으로 가수분해시켜 R이 메틸,에틸, n-프로필 알릴 또는 벤질이고, R1이 OH인 일반식(Ⅰ)화합물을 생성시키거나;
    (e) 일반식(Ⅰc) 화합물을 피롤리딘과 반응시켜 R 이 메틸,에틸, n-프로필,벤질 또는 알릴이고, R1이 1-피롤리디닐인 일반식(Ⅰ)화합물을 생성시키거나;
    (f) 일반식 (Ⅰd) 화합물을 (C1내지 C2) 알킬할라이드 또는 알릴할라이드로 알킬화시키고;
    (g) 임의로 트란스-(±)-라세미체를 그의 트란스-(-) 및 트란스-(+)-에난티오머로 단리시키며;
    (h) 생성된 일반식(Ⅰ) 화합물을 임의로 염화시켜 약제학적으로 무독한 산부가염을 생성시킴을 특징으로하여, 일반식(Ⅰ)의 트란스-(±)-라세미체, 또는 트란스-(-)또는 트란스-(+)-에난티오머 또는 그의 약제학적으로 무독한 산부가염을 제조하는 방법.
    상기 식에서, R은 H, 벤질, 메틸, 에틸, n-프로필 또는 알릴이고; R1은 H, OH, 할로겐, 메틸, NH2, NH(C1내지 C3알킬) N (C1내지 C3알킬)2, 1-피롤리디닐, NHCO(C1내지 C3알킬), 또는 NH(C1내지 C2알킬페닐)이며; R7은 H, 벤질, 메틸, 에틸, 또는 n-프로필이고; R4는 H,메틸, NH2, NH(C1내지 C3알킬), N(C1내지 C3알킬)2또는 NH(C1내지 C2알킬페닐)이며; R5는 메틸, 에틸, n-프로필, 알릴 또는 벤질이고; Z는 Cl, Br 또는 (C1내지 C3알킬)-CO-O-이며; X는 적절한 음이온이고; halo는 Ol 또는 Br이다.
  2. 제1항에 있어서, 트란스-(-)- 에난티오머를 제조하는 방법.
  3. 제1 또는 2항에 있어서, R이 n-프로필인 방법.
  4. 제1항의 방법(a)에 있어서, 트란스-(±)-1-n-프로필-6-옥소-7-브로모데카하이드로퀴놀린과 티오우레아를 반응시킴을 특징으로 하여 트란스-(±)-2-아미노-5-n-프로필-4,4a,5,6,7,8,8a,9-옥타하이드로티아졸로[4,5-g] 퀴놀린을 제조하는 방법.
  5. 제1항의 방법(a)에 있어서, 4aR, 8aR-1-n-프로필-6-옥소-7-브로모데카하이드로퀴놀린과 티오우레아를 반응시킴을 특징으로 하여 4aR, 8aR-2-아미노-5-n-프로필-4,4a,5,6,7,8,8a,9-옥타하이드로티아졸로[4,5-g] 퀴놀린을 제조하는 방법.
  6. 제1항의 방법(c)에 있어서, 트란스-(±)-5-n-프로필-4,4a,5,6,7,8,8a,9-옥타하이드로티아졸로[4,5-g] 퀴놀린-2-디아조늄 포스페이트와 수성차아인산을 반응시킴을 특징으로하여 트란스-(±)-5-n-프로필-4,4a,5,6,7,8,8a,9-옥타하이드로티아졸로[4,5-g] 퀴놀린을 제조하는 방법.
  7. 제1항의 방법(c)에 있어서, 트란스-(±)-5-n-프로필-4,4a,5,6,7,8,8a,6-옥타하이드로티아졸로[4,5-g] 퀴놀린-2-디아조늄 니트레이트와 구리분말 및 수성 HBr을 반응시킴을 특징으로 하여 트란스-(±)-2-브로모-5-n-프로필-4,4a,5,6,7,8,8a,9-옥타하이드로티아졸로[4,5-g] 퀴놀린을 제조하는 방법.
  8. 제1항의 방법(b)에 있어서, 트란스-(±)-2-아미노-5-n-프로필-4,4a,5,6,7,8,8a,9-옥타하이드로티아졸로[4,5-g] 퀴놀린을 아세틸클로라이드와 반응시킴을 특징으로하여 트란스--(±)-2-n-아세틸아미노-5-n-프로필-4,4a,5,6,7,8,8a,9-옥타하이드로티아졸로[4,5-g] 퀴놀린을 제조하는 방법.
  9. 제1항의 방법(a)에 있어서, 트란스-(±)-1-n-프로필-6-옥소-7-브로모데카하이드로퀴놀린을 N-메틸티오우레아와 반응시킴을 특징으로 하여 트란스-(±)-2-메틸아미노-5-n-프로필-4,4a,5,6,7,8,8a,9-옥타하이드로티아졸로[4,5-g] 퀴놀린을 제조하는 방법.
  10. 제1항의 방법(a)에 있어서, 트란스-(±)-1-n-프로필-6-옥소-7-브로모데카하이드로퀴놀린을 티오포름아미드와 반응시킴을 특징으로 하여 트란스-(±)-5-n-프로필-4,4a,5,6,7,8,8a,9-옥타하이드로티아졸로[4,5-g] 퀴놀린을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850002803A 1984-04-27 1985-04-25 옥타하이드로티아졸로[4,5-g] 퀴놀린의 제조방법 KR870001072B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/604,687 US4537893A (en) 1984-04-27 1984-04-27 Octahydrothiazolo[4,5-g]quinolines and use as prolactin secretion inhibitors
US604687 1984-04-27

Publications (2)

Publication Number Publication Date
KR850007261A true KR850007261A (ko) 1985-12-02
KR870001072B1 KR870001072B1 (ko) 1987-05-27

Family

ID=24420601

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850002803A KR870001072B1 (ko) 1984-04-27 1985-04-25 옥타하이드로티아졸로[4,5-g] 퀴놀린의 제조방법

Country Status (19)

Country Link
US (1) US4537893A (ko)
EP (1) EP0160502B1 (ko)
JP (1) JPH0631262B2 (ko)
KR (1) KR870001072B1 (ko)
CN (1) CN85101547A (ko)
AT (1) ATE67767T1 (ko)
AU (1) AU564946B2 (ko)
CA (1) CA1287356C (ko)
DE (1) DE3584183D1 (ko)
DK (1) DK185485A (ko)
ES (1) ES8704177A1 (ko)
GR (1) GR850989B (ko)
HU (1) HU193113B (ko)
IL (1) IL74988A0 (ko)
NZ (1) NZ211863A (ko)
PH (1) PH21951A (ko)
PT (1) PT80339B (ko)
SU (1) SU1414318A3 (ko)
ZA (1) ZA852999B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778894A (en) * 1983-09-26 1988-10-18 Eli Lilly And Company 6 oxo-decahydroquinolines
US4977160A (en) * 1986-06-16 1990-12-11 Eli Lilly And Company BCD tricyclic ergoline part-structure analogues
US4826986A (en) * 1986-06-16 1989-05-02 Eli Lilly And Company 6-Oxo-trans-octa- and decahydroquinolines
US5134143A (en) * 1986-06-16 1992-07-28 Eli Lilly And Company BCD tricyclic ergoline part-structure analogues
DE3624607A1 (de) * 1986-07-21 1988-01-28 Boehringer Ingelheim Kg Neue tetrahydrobenzothiazolo-chinoline ihre herstellung und verwendung
US4762843A (en) * 1986-09-15 1988-08-09 Warner-Lambert Company Hetero [f] fused carbocyclic pyridines as dopaminergic agents
US5006525A (en) * 1989-07-24 1991-04-09 Eli Lilly And Company Dopamine agonists method
US4977149A (en) * 1989-07-24 1990-12-11 Eli Lilly And Company Pyridoquinoline dopamine agonists, compositions and use
US5057515A (en) * 1989-07-24 1991-10-15 Eli Lilly And Company Method for agonizing a dopamine receptor
US4939259A (en) * 1989-07-24 1990-07-03 Eli Lilly And Company 2-oxo-pyrido[2,3-g]quinoline derivatives
US5416090A (en) * 1991-01-31 1995-05-16 Eli Lilly And Company Method of treating inflammation
EP0816406B1 (de) * 1996-06-26 2000-09-06 Bayer Ag Verfahren zur Herstellung salzarmer Präparationen von Kondensationsprodukten
CN102088998A (zh) * 2008-05-14 2011-06-08 益普生制药股份有限公司 生长激素释放抑制因子-多巴胺缀合物的药物组合物
TWI537274B (zh) 2011-03-14 2016-06-11 橘生藥品工業股份有限公司 新穎之八氫噻吩并喹啉衍生物、含有其之醫藥組成物及該等之用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2056224A1 (de) * 1969-11-17 1971-06-03 Danchi Seiyaku Co , Ltd , Tokio Neue Thiazolochinohnderivate und Ver fahren zu ihrer Herstellung
US4198415A (en) * 1979-01-22 1980-04-15 Eli Lilly And Company Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines
US4258049A (en) * 1979-07-02 1981-03-24 Smithkline Corporation Inhibiting phenylethanolamine N-methyltransferase with thiadiazolo and oxadiazolotetrahydroisoquinolines
US4367231A (en) * 1979-09-14 1983-01-04 Eli Lilly And Company Method of using octahydro pyrazolo[3,4-g]quinolines

Also Published As

Publication number Publication date
CA1287356C (en) 1991-08-06
PH21951A (en) 1988-04-15
EP0160502A3 (en) 1987-03-11
IL74988A0 (en) 1985-08-30
DE3584183D1 (de) 1991-10-31
CN85101547A (zh) 1987-01-24
PT80339B (en) 1987-02-16
EP0160502B1 (en) 1991-09-25
HU193113B (en) 1987-08-28
GR850989B (ko) 1985-11-25
DK185485A (da) 1985-10-28
HUT37624A (en) 1986-01-23
AU564946B2 (en) 1987-09-03
KR870001072B1 (ko) 1987-05-27
EP0160502A2 (en) 1985-11-06
PT80339A (en) 1985-05-01
ES8704177A1 (es) 1987-03-16
JPH0631262B2 (ja) 1994-04-27
DK185485D0 (da) 1985-04-25
JPS60233091A (ja) 1985-11-19
NZ211863A (en) 1987-10-30
ZA852999B (en) 1986-11-26
ES542565A0 (es) 1987-03-16
US4537893A (en) 1985-08-27
AU4166685A (en) 1985-10-31
ATE67767T1 (de) 1991-10-15
SU1414318A3 (ru) 1988-07-30

Similar Documents

Publication Publication Date Title
KR850007261A (ko) 옥타하이드로티아졸로[4,5-ｇ]퀴놀린의 제조방법
CA1238910A (en) CARBOXYALKENOIC ACIDS
NZ208254A (en) R-(-)- and s-(+)-4-(3-amino-2-hydroxypropoxy)-carbazoles, stereospecific preparations therefor, and pharmaceutical compositions
KR880002815A (ko) 약제학적 화합물
KR927003539A (ko) 2-니트로 이미다졸 유도체, 그의 제조방법 및 이를 유효성분으로 하는 방사선 증감제
KR910021366A (ko) 4-(4-알콕시페닐)-2-부틸아민 유도체 및 그의 제조방법
UA7228A1 (uk) Спосіб одержання похідних n-(4-індолілпіперідиноалкіл )бензімідазолону або їх солей з кислотами
KR850002480A (ko) 피라졸-환 알킬화된 피라졸로 퀴놀린의 제조방법
KR910016695A (ko) 4-(아미노메틸) 피페리딘 유도체, 그의 제조방법 및 치료에의 이용
JPS61227583A (ja) 新規な化学方法
KR840001157A (ko) 카르보스티릴 유도체의 제조방법
NO873815D0 (no) Nye naftylderivater og fremstilling derav.
KR850002260A (ko) 치환된 4-알킬-2(1h) 퀴나졸린온-1-알카노산 유도체의 제조방법
ES8505922A1 (es) Procedimiento para preparar nuevos derivados del acido 4-fenil-4-oxo-buten-2-oico
KR850002097A (ko) 2-메르캅토피리미도헥사하이드로퀴놀린 유도체의 제조방법
EP0147181A3 (en) Thiazolylacetic acid derivatives and their preparation
SU597339A3 (ru) Способ получени 6-аминопенициллановой или 7-аминоцефалоспорановой кислоты
KR890701593A (ko) 3-엑소메틸렌세팜유도체의 제조방법
KR860003212A (ko) 2-피리딘-티올 유도체 및 그의 산부가염의 제조 방법
ES8506009A1 (es) Un procedimiento para la preparacion de derivados de oxacefalosporina
KR840005426A (ko) 피리딜알킬 나이트레이트 화합물의 제조방법
KR860002451A (ko) 아미드 화합물의 제조방법
BR8601653A (pt) Processo para a preparacao de derivados heterociclicos de amida,composicoes fungicidas,processo para combate de fungos,utilizacao de tais derivados,e processo para preparacao de tais composicoes
ATE17851T1 (de) Imidazolylkarbonsaeure, deren derivate und herstellung.
KR940014351A (ko) 신규 피리미딘 티온 화합물 및 이의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee